User profiles for Willem F Lems
 | willem lemshoogleraar reumatologie, metabole botziekten Verified email at vumc.nl Cited by 24599 |
Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up
…, MT Nurmohamed, PA van Schouwenburg, WF Lems… - Jama, 2011 - jamanetwork.com
Context Short-term data on the immunogenicity of monoclonal antibodies showed associations
between the development of antidrug antibodies and diminished serum drug levels, and …
between the development of antidrug antibodies and diminished serum drug levels, and …
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
…, MT Nurmohamed, S Stapel, WF Lems… - Annals of the …, 2007 - ard.bmj.com
Background: A substantial proportion of patients with rheumatoid arthritis (RA) do not respond,
or lose initial response, to adalimumab treatment. One explanation for non-response is …
or lose initial response, to adalimumab treatment. One explanation for non-response is …
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study
…, YM Smulders, M Boers, WF Lems… - Arthritis Care & …, 2009 - Wiley Online Library
Objective Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular
disease (CVD), but longitudinal observations are limited and the precise magnitude is …
disease (CVD), but longitudinal observations are limited and the precise magnitude is …
Republished: Value of biomarkers in osteoarthritis: current status and perspectives
…, MA Karsdal, V Kraus, WF Lems… - Postgraduate …, 2014 - academic.oup.com
Osteoarthritis affects the whole joint structure with progressive changes in cartilage, menisci,
ligaments and subchondral bone, and synovial inflammation. Biomarkers are being …
ligaments and subchondral bone, and synovial inflammation. Biomarkers are being …
Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus
IEM Bultink, WF Lems, PJ Kostense… - Arthritis & …, 2005 - Wiley Online Library
Objective. To examine the prevalence of and risk factors for low bone mineral density (BMD)
and vertebral fractures in patients with systemic lupus erythematosus (SLE). Methods. We …
and vertebral fractures in patients with systemic lupus erythematosus (SLE). Methods. We …
[HTML][HTML] Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis–an expert consensus addressing benefits as well as gastrointestinal …
Background There are several guidelines addressing the issues around the use of NSAIDs.
However, none has specifically addressed the upper versus lower gastrointestinal (GI) risk …
However, none has specifically addressed the upper versus lower gastrointestinal (GI) risk …
Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort …
…, MT Nurmohamed, S Stapel, WF Lems… - Annals of the …, 2010 - ard.bmj.com
Objective To investigate how antibodies against anti-tumour necrosis factor (anti-TNF) agents
influence response after switching from infliximab to adalimumab in rheumatoid arthritis (…
influence response after switching from infliximab to adalimumab in rheumatoid arthritis (…
Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis
…, A Slöetjes, FPJG Lafeber, WF Lems… - Arthritis & …, 2012 - Wiley Online Library
Objective To investigate whether alarmins S100A8 and S100A9 are involved in mediating
cartilage destruction during murine and human osteoarthritis (OA). Methods Two different …
cartilage destruction during murine and human osteoarthritis (OA). Methods Two different …
[HTML][HTML] Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis
RNJ de Nijs, JWG Jacobs, WF Lems… - … England Journal of …, 2006 - Mass Medical Soc
Background Treatment with glucocorticoids is associated with bone loss starting soon after
therapy is initiated and an increased risk of fracture. Methods We performed a randomized, …
therapy is initiated and an increased risk of fracture. Methods We performed a randomized, …
[HTML][HTML] The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients
…, S de Ridder, MT Nurmohamed, WF Lems… - Arthritis research & …, 2012 - Springer
Introduction B cell depletion therapy is efficacious in rheumatoid arthritis (RA) patients failing
on tumor necrosis factor (TNF) blocking agents. However, approximately 40% to 50% of …
on tumor necrosis factor (TNF) blocking agents. However, approximately 40% to 50% of …